SGO 2024

Questions discussed in this category

What are your top takeaways from SGO 2024?

2 Answers available

Papers discussed in this category

Lancet (London, England), 2024 Mar 20

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.

N Engl J Med, 2023 Mar 27

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.

Lancet (London, England), 2023 Dec 01

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.

Related Topics